Difference between revisions of "Pixantrone (Pixuvri)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
| Line 17: | Line 17: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:EMA approved in 2012]] | [[Category:EMA approved in 2012]] | ||
Revision as of 00:22, 23 September 2023
Mechanism of action
From the NCI Drug Dictionary: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. Route: IV
Diseases for which it is used
History of changes in EMA indication
- 2012-05-10: Initial authorization as Pixuvri
- Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
Also known as
- Code name: BBR-2778
- Generic name: pixantrone dimaleate
- Brand name: Pixuvri